Metastatic Lung Non-Squamous Non-Small Cell Carcinoma

7 clinical trials · Condition

Record	Firm	Date
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer (NCT05017025)	M.D. Anderson Cancer Center	2022-02-17
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer (NCT04971187)	M.D. Anderson Cancer Center	2021-06-30
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (NCT04181060)	National Cancer Institute (NCI)	2020-12-28
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (NCT04310007)	National Cancer Institute (NCI)	2020-07-13
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy (NCT03965689)	National Cancer Institute (NCI)	2020-04-16
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer (NCT03468985)	National Cancer Institute (NCI)	2018-05-07
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer (NCT02520778)	National Cancer Institute (NCI)	2016-08-30

Every clearance here is in the API, with alerts when new ones post.